Recently, in accordance with the Announcement on the Filing of the Second Batch of High-Tech Enterprises Identified and Filed by the Jiangsu Identification Institution in 2025 issued by the Office of the National Leading Group for the Administration of High-Tech Enterprise Identification, Zhongke Jiangsu Pharmaceutical, the second production base of Zhongke Health Industry Group, has successfully passed the identification and been awarded the title of “High-Tech Enterprise”. This marks that Zhongke’s comprehensive capabilities in technological innovation, R&D strength and achievement transformation have received authoritative national recognition.
National High-Tech Enterprise
The identification of National High-Tech Enterprises is organized in accordance with the Administrative Measures for the Identification of High-Tech Enterprises and its supporting guidelines jointly issued by the Ministry of Science and Technology, the Ministry of Finance and the State Taxation Administration. It involves systematic and high-standard evaluation across multiple dimensions including core independent intellectual property rights, the ability to transform scientific and technological achievements, the management level of research and development organizations, and enterprise growth potential. It is an important symbol of the innovation strength of science and technology-based enterprises in China.
As an important production base of the Group, Zhongke Jiangsu Pharmaceutical has successfully obtained this certification, forming a dual National High-Tech Enterprise synergy with Nanjing Zhongke Pharmaceutical, another subsidiary of the Group that already holds the National High-Tech Enterprise qualification. Together, they have built a dual-core driving system for Zhongke in the R&D and production of biomedicine and health products. Leveraging the Group’s long-term scientific research accumulation in the extraction and application of natural plant extracts such as ganoderma, cordyceps and lycopene, the two bases will continue to advance technological upgrading and innovation across the entire industrial chain, from raw material processing technologies to end products.
In recent years, Zhongke has been continuously increasing its R&D investment and built an integrated scientific research system covering basic research, process development, clinical verification and industrial transformation, while establishing in-depth industry-university-research cooperation with a number of universities and research institutions. The certification of Zhongke Jiangsu Pharmaceutical Production Base is not only a recognition of Zhongke’s overall innovation strength, but also will further enhance the Group’s market competitiveness and supply capacity in the field of high-end health products.
Looking ahead, Zhongke will continue to take technological innovation as its core driving force, deepen cutting-edge exploration in the fields of biomedicine and health technology, promote the transformation of more scientific research achievements into practical productive forces, and contribute more scientific and technological wisdom and corporate strength to supporting the Healthy China initiative and meeting the people’s demand for a high-quality healthy life.
EN 
CN